ABBV-142
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 18, 2025
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
(clinicaltrials.gov)
- P2 | N=165 | Not yet recruiting | Sponsor: AbbVie
Adverse events • New P2 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1